JOP20210129A1 - مثبطات apol1 وطرق استخدامها - Google Patents
مثبطات apol1 وطرق استخدامهاInfo
- Publication number
- JOP20210129A1 JOP20210129A1 JOP/2021/0129A JOP20210129A JOP20210129A1 JO P20210129 A1 JOP20210129 A1 JO P20210129A1 JO P20210129 A JOP20210129 A JO P20210129A JO P20210129 A1 JOP20210129 A1 JO P20210129A1
- Authority
- JO
- Jordan
- Prior art keywords
- same
- methods
- apol1
- inhibitors
- ndkd
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/69—Boron compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/695—Silicon compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic System
- C07F5/02—Boron compounds
- C07F5/025—Boronic and borinic acid compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic System
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/0803—Compounds with Si-C or Si-Si linkages
- C07F7/081—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
- C07F7/0812—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring
- C07F7/0814—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring said ring is substituted at a C ring atom by Si
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic System
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/0803—Compounds with Si-C or Si-Si linkages
- C07F7/081—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
- C07F7/0812—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring
- C07F7/0816—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring said ring comprising Si as a ring atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/46—Phosphinous acids R2=P—OH; Thiophosphinous acids; Aminophosphines R2-P-NH2 including R2P(=O)H; derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6564—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
- C07F9/6581—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and nitrogen atoms with or without oxygen or sulfur atoms, as ring hetero atoms
- C07F9/6584—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and nitrogen atoms with or without oxygen or sulfur atoms, as ring hetero atoms having one phosphorus atom as ring hetero atom
- C07F9/65842—Cyclic amide derivatives of acids of phosphorus, in which one nitrogen atom belongs to the ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Urology & Nephrology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
غير متوفر
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862780667P | 2018-12-17 | 2018-12-17 | |
PCT/US2019/066746 WO2020131807A1 (en) | 2018-12-17 | 2019-12-17 | Inhibitors of apol1 and methods of using same |
Publications (1)
Publication Number | Publication Date |
---|---|
JOP20210129A1 true JOP20210129A1 (ar) | 2023-01-30 |
Family
ID=69182627
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JOP/2021/0131A JOP20210131A1 (ar) | 2018-12-17 | 2019-12-17 | مثبطات apol1 وطرق استخدامها |
JOP/2021/0130A JOP20210130A1 (ar) | 2018-12-17 | 2019-12-17 | مثبطات apol1 وطرق استخدامها |
JOP/2021/0129A JOP20210129A1 (ar) | 2018-12-17 | 2019-12-17 | مثبطات apol1 وطرق استخدامها |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JOP/2021/0131A JOP20210131A1 (ar) | 2018-12-17 | 2019-12-17 | مثبطات apol1 وطرق استخدامها |
JOP/2021/0130A JOP20210130A1 (ar) | 2018-12-17 | 2019-12-17 | مثبطات apol1 وطرق استخدامها |
Country Status (23)
Country | Link |
---|---|
US (2) | US11618746B2 (ar) |
EP (1) | EP3897833A1 (ar) |
JP (1) | JP2022515369A (ar) |
KR (1) | KR20210116483A (ar) |
CN (1) | CN113453760A (ar) |
AR (1) | AR116913A1 (ar) |
AU (1) | AU2019405477A1 (ar) |
BR (1) | BR112021011564A2 (ar) |
CA (1) | CA3121910A1 (ar) |
CL (1) | CL2021001561A1 (ar) |
CO (1) | CO2021009053A2 (ar) |
CR (1) | CR20210383A (ar) |
DO (1) | DOP2021000116A (ar) |
EC (1) | ECSP21052184A (ar) |
IL (1) | IL283592A (ar) |
JO (3) | JOP20210131A1 (ar) |
MA (1) | MA54538A (ar) |
MX (1) | MX2021007152A (ar) |
PE (1) | PE20212302A1 (ar) |
SG (1) | SG11202105769XA (ar) |
TW (1) | TW202039471A (ar) |
UY (1) | UY38514A (ar) |
WO (1) | WO2020131807A1 (ar) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MA54538A (fr) | 2018-12-17 | 2021-10-27 | Vertex Pharma | Inhibiteurs d'apol1 et leurs procédés d'utilisation |
AU2021213758A1 (en) * | 2020-01-29 | 2022-09-01 | Vertex Pharmaceuticals Incorporated | Inhibitors of APOL1 and methods of using same |
WO2021158666A1 (en) * | 2020-02-04 | 2021-08-12 | Vertex Pharmaceuticals Incorporated | Solid forms of apol1 inhibitor and methods of using same |
IL296035A (en) | 2020-03-06 | 2022-10-01 | Vertex Pharma | Treatment methods for apol-1 dependent focal segmental tuberous sclerosis |
CR20230132A (es) | 2020-08-26 | 2023-06-27 | Vertex Pharma | Inhibidores de apol1 y métodos para usar los mismos |
AU2022334580A1 (en) * | 2021-08-26 | 2024-03-07 | Vertex Pharmaceuticals Incorporated | Solid forms of spirotricyclic apol1 inhibitors and methods of using same |
WO2023101981A1 (en) * | 2021-11-30 | 2023-06-08 | Vertex Pharmaceuticals Incorporated | Spirocyclic inhibitors of apol1 and methods of using same |
WO2023141432A2 (en) | 2022-01-18 | 2023-07-27 | Maze Therapeutics, Inc. | Apol1 inhibitors and methods of use |
WO2023154344A1 (en) * | 2022-02-08 | 2023-08-17 | Vertex Pharmaceuticals Incorporated | 2-methyl-4',5'-dihydrospiro[piperidine-4,7'-thieno[2,3-c]pyran] derivatives as inhibitors of apol1 and methods of using same |
WO2023194895A1 (en) | 2022-04-06 | 2023-10-12 | Glaxosmithkline Intellectual Property Development Limited | Pyrrol derivatives as inhibitors of apolipoprotein l-1 |
WO2024040235A1 (en) * | 2022-08-19 | 2024-02-22 | Maze Therapeutics, Inc. | Apol1 inhibitors and methods of use |
Family Cites Families (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2801585B1 (fr) | 1999-11-25 | 2002-02-15 | Fournier Ind & Sante | Nouveaux antagonistes des recepteurs de l'ii-8 |
EP1324985A4 (en) | 2000-10-02 | 2004-10-06 | Merck & Co Inc | PRENYL PROTEIN TRANSFERASE INHIBITORS |
FR2824827B1 (fr) | 2001-05-17 | 2004-02-13 | Fournier Lab Sa | Nouveaux derives de 5-phenyl-1h-indole antagoniste des recepteurs de l'interleukine-8 |
FR2824826B1 (fr) | 2001-05-17 | 2003-11-07 | Fournier Lab Sa | Nouveaux derives de 5-cyano-1h-indole antagonistes des recepteurs de l'interleukine-8 |
MXPA04004657A (es) | 2001-11-14 | 2004-08-13 | Teva Pharma | Formas amorfas y cristalinas de potasio de losartan y proceso para su preparacion. |
AU2003237593A1 (en) * | 2002-06-05 | 2003-12-22 | Natco Pharma Limited | Process for the preparation of 4-(4-fluorobenzoyl) butyric acid |
US8053440B2 (en) * | 2007-02-01 | 2011-11-08 | Resverlogix Corporation | Compounds for the prevention and treatment of cardiovascular diseases |
JP5323834B2 (ja) | 2007-08-17 | 2013-10-23 | エルジー・ライフ・サイエンシーズ・リミテッド | 細胞壊死阻害剤としてのインドール化合物 |
JP5685203B2 (ja) | 2009-05-29 | 2015-03-18 | ラクオリア創薬株式会社 | カルシウムチャネル遮断薬またはナトリウムチャネル遮断薬としてのアリール置換カルボキサミド誘導体 |
US10130632B2 (en) | 2012-11-27 | 2018-11-20 | Beth Israel Deaconess Medical Center, Inc. | Methods for treating renal disease |
US9850203B2 (en) * | 2013-09-26 | 2017-12-26 | Pharmakea, Inc. | Autotaxin inhibitor compounds |
WO2016029310A1 (en) | 2014-08-27 | 2016-03-03 | The Governing Council Of The University Of Toronto | Cannabinoid type 1 receptor modulators |
US10654838B2 (en) | 2014-10-08 | 2020-05-19 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Aminopyridine compounds useful as inhibitors of protein prenylation |
ES2865199T3 (es) | 2015-08-27 | 2021-10-15 | Pfizer | Compuestos de heteroarilo o arilo condensados bicíclicos como moduladores de IRAK4 |
MA54538A (fr) | 2018-12-17 | 2021-10-27 | Vertex Pharma | Inhibiteurs d'apol1 et leurs procédés d'utilisation |
AU2021213758A1 (en) | 2020-01-29 | 2022-09-01 | Vertex Pharmaceuticals Incorporated | Inhibitors of APOL1 and methods of using same |
WO2021158666A1 (en) | 2020-02-04 | 2021-08-12 | Vertex Pharmaceuticals Incorporated | Solid forms of apol1 inhibitor and methods of using same |
IL296035A (en) * | 2020-03-06 | 2022-10-01 | Vertex Pharma | Treatment methods for apol-1 dependent focal segmental tuberous sclerosis |
EP4165022A1 (en) | 2020-06-12 | 2023-04-19 | Vertex Pharmaceuticals Incorporated | Inhibitors of apol1 and use of the same |
WO2021252863A1 (en) | 2020-06-12 | 2021-12-16 | Vertex Pharmaceuticals Incorporated | Solid forms of apol1 inhibitor and using the same |
WO2021252849A1 (en) | 2020-06-12 | 2021-12-16 | Vertex Pharmaceuticals Incorporated | Inhibitors of apol1 and use of the same |
CR20230132A (es) | 2020-08-26 | 2023-06-27 | Vertex Pharma | Inhibidores de apol1 y métodos para usar los mismos |
-
2019
- 2019-12-17 MA MA054538A patent/MA54538A/fr unknown
- 2019-12-17 JO JOP/2021/0131A patent/JOP20210131A1/ar unknown
- 2019-12-17 UY UY0001038514A patent/UY38514A/es unknown
- 2019-12-17 JP JP2021534284A patent/JP2022515369A/ja active Pending
- 2019-12-17 WO PCT/US2019/066746 patent/WO2020131807A1/en active Application Filing
- 2019-12-17 CN CN201980092356.3A patent/CN113453760A/zh active Pending
- 2019-12-17 TW TW108146307A patent/TW202039471A/zh unknown
- 2019-12-17 CR CR20210383A patent/CR20210383A/es unknown
- 2019-12-17 US US16/717,099 patent/US11618746B2/en active Active
- 2019-12-17 CA CA3121910A patent/CA3121910A1/en active Pending
- 2019-12-17 AR ARP190103717A patent/AR116913A1/es unknown
- 2019-12-17 SG SG11202105769XA patent/SG11202105769XA/en unknown
- 2019-12-17 MX MX2021007152A patent/MX2021007152A/es unknown
- 2019-12-17 AU AU2019405477A patent/AU2019405477A1/en active Pending
- 2019-12-17 BR BR112021011564-1A patent/BR112021011564A2/pt not_active Application Discontinuation
- 2019-12-17 EP EP19839496.7A patent/EP3897833A1/en active Pending
- 2019-12-17 PE PE2021000896A patent/PE20212302A1/es unknown
- 2019-12-17 KR KR1020217022550A patent/KR20210116483A/ko unknown
- 2019-12-17 JO JOP/2021/0130A patent/JOP20210130A1/ar unknown
- 2019-12-17 JO JOP/2021/0129A patent/JOP20210129A1/ar unknown
-
2021
- 2021-05-31 IL IL283592A patent/IL283592A/en unknown
- 2021-06-15 DO DO2021000116A patent/DOP2021000116A/es unknown
- 2021-06-15 CL CL2021001561A patent/CL2021001561A1/es unknown
- 2021-07-09 CO CONC2021/0009053A patent/CO2021009053A2/es unknown
- 2021-07-15 EC ECSENADI202152184A patent/ECSP21052184A/es unknown
-
2023
- 2023-02-07 US US18/106,569 patent/US20230271945A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
CO2021009053A2 (es) | 2021-08-09 |
US20200377479A1 (en) | 2020-12-03 |
AU2019405477A1 (en) | 2021-06-24 |
US20230271945A1 (en) | 2023-08-31 |
IL283592A (en) | 2021-07-29 |
CN113453760A (zh) | 2021-09-28 |
EP3897833A1 (en) | 2021-10-27 |
PE20212302A1 (es) | 2021-12-10 |
MX2021007152A (es) | 2021-11-03 |
CR20210383A (es) | 2021-09-22 |
KR20210116483A (ko) | 2021-09-27 |
JOP20210131A1 (ar) | 2023-01-30 |
AR116913A1 (es) | 2021-06-23 |
JP2022515369A (ja) | 2022-02-18 |
ECSP21052184A (es) | 2021-08-31 |
UY38514A (es) | 2020-07-31 |
TW202039471A (zh) | 2020-11-01 |
DOP2021000116A (es) | 2021-09-30 |
MA54538A (fr) | 2021-10-27 |
US11618746B2 (en) | 2023-04-04 |
JOP20210130A1 (ar) | 2023-01-30 |
CA3121910A1 (en) | 2020-06-25 |
SG11202105769XA (en) | 2021-07-29 |
CL2021001561A1 (es) | 2021-11-26 |
WO2020131807A1 (en) | 2020-06-25 |
BR112021011564A2 (pt) | 2021-08-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CR20210383A (es) | Inhibidores de apol 1 y sus métodos de uso | |
CR20200347A (es) | Inhibidores pd-1/pd-l1 | |
CR20200376A (es) | Inhibidores de cd73 | |
GEP20237506B (en) | Pcsk9 antagonist compounds | |
CO2021005884A2 (es) | Moduladores de la alfa-1 antitripsina | |
EA201891268A1 (ru) | Соединения, которые можно применять в качестве ингибиторов киназы | |
EA202191084A1 (ru) | Соединения пиридазинонов и их применения | |
GEP20227443B (en) | Magl inhibitors | |
EA202092086A1 (ru) | Ингибиторы аргиназы | |
MX2021005348A (es) | Compuestos de piridazinonas y usos de los mismos. | |
EA202190073A1 (ru) | Композиции и способы лечения видов гемоглобинопатии и талассемии | |
PH12021500008A1 (en) | Transglutaminase 2 (tg2) inhibitors | |
MX2023002269A (es) | Inhibidores de apol1 y metodos para usar los mismos. | |
MX2021003187A (es) | Inhibición de la peptidasa específica de ubiquitina 9x. | |
MX2022007841A (es) | Degradadores del regulador dependiente de actina asociado a la matriz relacionado con el complejo switch/sacarosa no fermentable de la subfamilia a de la cromatina (smarca)y usos de los mismos. | |
MX2020012281A (es) | Composiciones que comprenden compuestos de bisfluoroalquil-1,4-ben zodiacepinona y metodos de uso de las mismas. | |
MX2021003843A (es) | Inhibidores de la interaccion yap/taz-tead y su uso en el tratamiento del cancer. | |
CL2020003010A1 (es) | Moduladores de la expresión de apol1 | |
WO2019026065A3 (en) | Novel braf inhibitors and use thereof for treatment of cutaneous reactions | |
CL2022001452A1 (es) | Inhibidores de masp-2 y métodos de uso. | |
MX2021010603A (es) | Inhibidores de caspasa y metodos de uso de los mismos. | |
JOP20210143A1 (ar) | تركيبات وطرق لعلاج ومنع التصلب الجانبي الضموري | |
EA201891240A1 (ru) | 1,3,4-тиадиазольные соединения и их применение в лечении рака | |
WO2020102243A3 (en) | In-flow photooxygenation of aminothienopyridinones generates novel ptp4a3 phosphatase inhibitors | |
EA202190766A1 (ru) | Иммуномодуляторы, их композиции и способы применения |